Skip to Content

The price target for Avanos Medical (NYSE:AVNS) has been raised to $26.00.

The price target for Avanos Medical (NYSE:AVNS) has been raised to $26.00.

In a research report released on Friday, analysts at Morgan Stanley increased their price objective on Avanos Medical (NYSE: AVNS). Benzinga reported this. The new price target is going to be $26.00. Based on their analysis, the brokerage company has placed the stock in the “underweight” category. In addition, the price objective that Morgan Stanley has set for the stock is to sell it at a price lower than the price it was trading at the end of the previous trading day.
In addition to those reports, there have been many others concerning AVNS. KeyCorp lowered its target price for Avanos Medical from $38.00 to $34.00 based on research that was made public on November 3. Despite this modification, the financial services company maintained its “overweight” rating on the stock. TheStreet has upgraded its previous rating of “d+” for Avanos Medical to its current grade of “c,” as stated in a study published on November 2. According to a report regarding Avanos Medical published by on December 15, the recommendation for the company’s stock was to “strongly buy” the stock.
On Friday, the opening price of a share of Avanos Medical was $26.92. Trading began at that time. The stock’s price has maintained a moving average of $25.43 over the past 200 trading days, while its moving average over the last 50 trading days has been $26.00. The company has a price-to-earnings ratio of 29.91, a market capitalization of $1.25 billion, and a beta value of 0.88. The company’s price-to-earnings ratio is one of the highest in the industry. In addition, a debt-to-equity ratio of 0.20 can be found, while the current ratio comes in at 2.90, and the quick ratio sits at 1.70. As a result, the price of Avanos Medical may range anywhere from $19.32 to $35.91 over a single year.
On November 2, the most recent earnings report for Avanos Medical was made public. Avanos Medical is a company that trades on the New York Stock Exchange (NYSE) under the symbol AVNS. The company reported earnings per share (EPS) of $0.38 for the period, which was $0.03 higher than the estimated floating around the internet, which was $0.35. The company’s sales for the quarter came in at $202 million, which is a number that is significantly lower than the general expectation of $205.47 million, which market analysts compiled. The company’s return on equity and net margin was 5.74 percent, with the net margin coming in at 5.39 percent. Compared to the previous year, the company’s revenue saw a 9.8% increase. The company posted earnings of $0.25 per share for the same period the year before when compared to the current year. The analysts who follow the market speculate that Avanos Medical will generate earnings of 1.52 cents per share this year.
Recently, a number of hedge funds and other types of institutional investors have been buying and selling company shares. Other types of institutional investors have also been involved in this activity. Fulton Bank, National Association completed the acquisition of approximately 216 thousand dollars worth of Avanos Medical shares during the last three months of 2018. In addition, the Teachers Retirement System of Kentucky started a new investment during the third quarter of the fiscal year, comprised of approximately 319 thousand dollars worth of Avanos Medical shares. During the third quarter, The Neuberger Berman Group LLC increased the proportion of its holdings of Avanos Medical by 5.4%. As a result of the recent acquisition of 44,361 additional shares during the most recent fiscal quarter, Neuberger Berman Group LLC now has a total of 870,524 shares of the company, valued at $18,980,000. This brings the total number of shares owned by the company to 870,524. During the third quarter of 2018, the Public Employees Retirement System of Ohio increased the percentage of Avanos Medical stock owned by 15.0%. The Public Employees Retirement System of Ohio now has a total of 85,582 shares of the company’s stock, which are worth a combined total of $1,864,000 after purchasing an additional 11,164 shares during the preceding quarter. And finally, during the third quarter, Algert Global LLC saw a growth in the number of shares held in Avanos Medical, which was 5.4% larger than it had been during the previous quarter. Algert Global LLC now has 40,115 shares in the corporation, with a value of $874,000. This was made possible due to purchasing an additional 2,039 shares during the most recent fiscal quarter. Institutional investors and hedge funds are the current owners of 92.08 percent of the company’s stock.
Avanos Medical, Inc. is a medical technology company that operates in North America, Europe, the Middle East, Africa, and Asia Pacific. Additionally, Latin America is one of their primary markets. The provision of services and products related to medical equipment is the company’s primary focus. It offers a wide range of products for long-term care under the brand names Ballard, Microcuff, and Endoclear. In addition, products like closed airway suction systems and other airway management tools are included in this category of goods: Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.


Leave a comment

Your email address will not be published. Required fields are marked *